evenfolio

Healthcare · NSE: YATHARTH

Yatharth Hospital & Trauma Care Services

Q2 FY27 earnings and concall highlights

Price as of 16 Nov 2026
1,069.05+0.77%

Q2 FY27 earnings call · Guided by management

Call held 4 Nov 2026 · Read the filing on NSEFiling

24​%EBITDA margin · upcoming yearsTyagi · Q&A · p. 14
₹100​CrAmount spent on Gurugram facility · GurugramTyagi · Q&A · p. 11
30​%Revenue growth (organic plan) · next three to four yearsTyagi · Q&A · p. 10
3​×Multiple of current numbers · next 3.5 to 4 yearsTyagi · Q&A · p. 10
M.Cap
₹10,301Cr
P/E
54.9×
1Y return
+34.51%
From 52W high
−9.7%

Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.

Share price

Results Q2 FY27, as filed · consolidated · ₹ Cr

Q2 FY27Q2 FY26YoYQ1 FY27QoQ
Revenue431279+54.4%393+9.9%
EBITDA10265+58.1%92+11.3%
EBITDA margin23.6%23.1%+56 bps23.4%+30 bps
PBTProfit before tax6655+19.7%61+7.2%
Net profit5141+22.7%47+7.5%
EPS (₹)5.254.28+22.7%4.88+7.6%

From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures.

Guidance

Revenue growth · long term30%Organic revenue growth of 30% a year seen for the next three to four years
Revenue · long term2.50 xOrganic 30% revenue growth over 3.5 years translates to almost 2.5x
EBITDA margin · long term24%EBITDA margins to stay upwards of 24% and rising in the upcoming years (existing plan)
Capacity · long term5,000 bedsOrganic 5,000-bed plan to be funded through internal accruals

EBITDA margin guidance unchanged despite oncology pricing difference

Yatharth Tyagi · Whole · Q&A · p. 14
“I think the guidance remains the same. In fact, we also have to cover up the difference from the oncology pricing differences. But we remain sure that the guidance we have for the EBITDA margins will continue to be the same.”

Group ARPOB expected to improve in coming years as premium hospitals scale up

Pankaj Prabhakar · Group Chief Financial Officer · p. 5
“As some of our newer and premium hospitals are scaling up and the specialty mix continues to improve, we expect our group ARPOB to improve meaningfully in the coming years.”

Group EBITDA guidance will not change because of the cancer drug pricing policy

Yatharth Tyagi · Whole · Q&A · p. 8
“Our overall group level EBITDA will not change going forward because of this policy.”

More figures from the call

Company · Guidance
70​%EBITDA to OCF conversion · end of the year
“That is why you would see a slight dip in the OCF conversion rate. But at the end of the year, we should expect upwards of 70% conversion.”
Ashutosh Kumar Jha · Group Chief · Q&Ap. 9
Company · Capacity
7,000–8,000​bedsBed capacity · next three to five years
“With Advent as a partner, we now aim to build a larger franchise of 7,000 to 8,000 beds over the next three to five years.”
Yatharth Tyagi · Wholep. 4
Company · Capacity
5,000​bedsBed capacity (organic) · three to four years
“The breakup of the expansion is that on our existing organic plan, we had announced going to 5,000 bed capacity, close to three to four years going forward. That remains the same.”
Yatharth Tyagi · Whole · Q&Ap. 8
Company · Capacity
2,000–3,000​bedsBeds added from Advent deal · close to four years
“On top of that, around 2,000 to 3,000 beds we expect to add because of this recent deal, again, in close to four years going forward.”
Yatharth Tyagi · Whole · Q&Ap. 8
Company · Capacity
40–50​%Share of acquired beds going live · from the next financial year
“So maybe around 40%-50% of those beds can actually go live from the next financial year itself.”
Yatharth Tyagi · Whole · Q&Ap. 9
Gurugram · Capacity
250​bedsHospital beds · next financial year
“Next is Gurugram, our upcoming 250-bedded hospital in Sector 40, which is progressing well and is expected to operationalize in the next financial year.”
Yatharth Tyagi · Wholep. 5

In short

  1. 01Advent International to invest INR3,150 crore via preferential issue; first tranche INR1,750 crore after CCI approval.
  2. 02Company aims for 7,000 to 8,000 beds over the next three to five years.
  3. 03Organic plan of 5,000 beds kept; Advent money to add about 2,000 beds by acquiring EBITDA-positive hospitals.
  4. 04EBITDA margin guidance of upwards of 24% kept despite about 0.3% hit from cancer drug margin cap.
  5. 05Organic revenue growth of 30% a year seen for the next three to four years.
  6. 06Q2 FY27 revenue INR4,314 million, up 52%; EBITDA INR1,020 million, margin 23.6%.
  7. 07Model Town Delhi hospital expected to break even in December; Gurugram 250-bed hospital due next financial year.
  8. 08Management says debt is at its peak level and will go down from here.

Capex

Model Town, Delhi: Radiation oncology at Model Town expected in about eight to nine months

8–9​months
Yatharth Tyagi · Whole · Q&A · p. 13
“As Amit mentioned, we will be adding radiation oncology in that hospital. I think the timeline should be somewhere around close to eight to nine months.”

Gurugram Sector 40: Gurugram building being modified; rest of construction to start after plan approval

Ashutosh Kumar Jha · Group Chief · Q&A · p. 16
“We have submitted the plans also, and we have started modifying the existing building according to the plan. As soon as we get the plan approval, we will start the construction on the remaining part of it.”

Agra: Agra facility to be renovated and more beds added

Yatharth Tyagi · Whole · Q&A · p. 12
“I think going forward, we are not just optimizing payer mix there, but we are planning to renovate the facility as well as add certain more beds, and certain floors are also in a renovation stage there.”

Faridabad Sector-20: Radiation and nuclear oncology at Faridabad Sector-20 to start in next two months

Amit Kumar Singh · Group Chief Executive Officer · Q&A · p. 13
“The radiation and nuclear, we're going to start in the next two months. So, this is Sector 20.”

Greater Noida: Nuclear and radiation oncology to be added at Greater Noida

Amit Kumar Singh · Group Chief Executive Officer · Q&A · p. 17
“And we are very confident that in Greater Noida, when we have our entire spectrum, and very soon we are going to add nuclear as well as radiation oncology in Greater Noida facility as well.”

Capacity

Occupancy 72% on currently operational beds

Yatharth Tyagi · Whole · p. 4
“Our occupancy stood at a healthy 72% on the currently operationalized beds.”

Faridabad, Model Town, Agra: About 350 to 400 beds yet to be opened at Faridabad, Model Town and Agra

Yatharth Tyagi · Whole · p. 4
“As we ramp up, about 350 to 400 beds are yet to be operationalized across Faridabad, Model Town, and Agra, presenting meaningful headroom for growth.”

All remaining beds expected to open within two to three quarters

2–3​quarters
Ashutosh Kumar Jha · Group Chief · Q&A · p. 7
“I think within the next couple of quarters, maybe two to three quarters, we should be opening all the beds.”

Model Town, Faridabad, Agra: Occupancy: Model Town 41%, new Faridabad 59%, Agra 58%

Nitin Gupta · President Finance and Group Chief Operating Officer · Q&A · p. 7
“However, as you asked about Model Town, it has increased to 41% in this quarter. The new hospital at Faridabad has increased to 59%, and Agra has been at 58% as of now.”

Noida, Greater Faridabad, Jhansi: No brownfield expansion plans at Noida, Greater Faridabad and Jhansi

Yatharth Tyagi · Whole · Q&A · p. 14
“But there are no specific plans for any brownfield capacity expansion in those hospitals.”

Segments

Gurugram: Gurugram hospital expected ARPOB above INR50,000

Yatharth Tyagi · Whole · p. 5
“The hospital is expected to serve the premium Gurugram market, given its location in a high-potential catchment and its proximity to the Delhi airport, with an anticipated ARPOB of above INR50,000.”

Gurugram: Gurugram hospital targeted to break even in 15 months

Yatharth Tyagi · Whole · Q&A · p. 15
“I think Gurugram, we are also targeting to break even in 15 months.”

Model Town, Delhi: December expected to be break-even month for Delhi Model Town hospital

Amit Kumar Singh · Group Chief Executive Officer · Q&A · p. 13
“Next quarter, we are very sure that December will be the break-even month for the Delhi hospital.”

Model Town, Delhi: Model Town losses fell from INR55 million in Q1 to INR38 million in Q2

₹3.8​Cr
Amit Kumar Singh · Group Chief Executive Officer · Q&A · p. 13
“For Q1, losses were INR55 million. This quarter we reported losses of INR38 million.”

Model Town, Delhi: Model Town Q2 revenue about INR26 crores with ARPOB around INR50,000

Yatharth Tyagi · Whole · p. 4
“In quarter 2, it reported revenue of approximately INR26 crores and ARPOB of around INR50,000, which places it among the premium hospitals in NCR, alongside Noida Extension, where ARPOB has also crossed INR50,000.”

Demand

international: International business still single digit share; CIS among contributing regions

Amit Kumar Singh · Group Chief Executive Officer · Q&A · p. 11
“However, it is still in single digits as a share of the top line, but we are making a very significant move and various regions like CIS are contributing.”

international: Noida airport opening for international market expected to add to international business

Amit Kumar Singh · Group Chief Executive Officer · Q&A · p. 11
“The next three to four years are going to be fantastic because Noida airport has still not opened for the international market. That is going to be a significant addition for us.”

Greater Noida oncology: No impact on oncology volumes from nearby new cancer centre

Yatharth Tyagi · Whole · Q&A · p. 16
“So, so far there is no impact in terms of the volume.”

international: International business grew more than 35% in H1 this year vs H2 last year

Amit Kumar Singh · Group Chief Executive Officer · Q&A · p. 11
“this year H1, our international business has grown by more than 35%.”

Greater Noida oncology: Oncology volume increased at Greater Noida and Noida Extension; more doctors being added

Yatharth Tyagi · Whole · Q&A · p. 16
“In fact, if you look at it, our absolute volume of oncology business has increased in both these hospitals. We are adding more doctors also in terms of leading doctors of NCR.”

Margins and costs

Q2 EBITDA INR1,020 million, up 50%; EBITDA margin 23.6%

Pankaj Prabhakar · Group Chief Financial Officer · p. 6
“Quarter 2 EBITDA was a record INR1,020 million, increasing 50% year-on-year and 11% quarter-on-quarter. EBITDA margin improved to 23.6% as the newer hospitals are now running profitably.”

Adjusted EBITDA margin 28% excluding New Delhi and Faridabad Sector-20 ramp-up losses

Pankaj Prabhakar · Group Chief Financial Officer · p. 6
“Excluding the ramp-up losses at New Delhi and Faridabad Sector-20, our adjusted EBITDA margin was healthy at 28%.”

Noida, Greater Noida, Noida Extension, Jhansi-Orchha: Existing hospitals' EBITDA margin upwards of 28%

Yatharth Tyagi · Whole · p. 3
“These have been true contributors to our profitability, with an EBITDA margin upwards of 28% for these specific hospitals.”

oncology: Plans to offset 0.3% cancer drug impact through other operating efficiencies

Yatharth Tyagi · Whole · Q&A · p. 8
“For this 0.3% reduction in cancer drugs, we are already figuring out and coming up with strategies to compensate this into other operational efficiencies and line items and other ways of compensating for this.”

Faridabad, Delhi: Faridabad and Delhi hospitals to start offsetting any margin drag

Amit Kumar Singh · Group Chief Executive Officer · Q&A · p. 14
“Just remember that our existing hospitals, particularly Faridabad and Delhi, will start contributing to offset whatever the drag would be.”

Debt and working capital

H1 operating cash flow INR1,113 million, up 49% year-on-year

Pankaj Prabhakar · Group Chief Financial Officer · p. 6
“Our operating cash flow during H1 was INR1,113 million, an increase of 49% year-on-year.”

Cash and bank INR4,289 million; net debt INR392 million at September 30, 2026

₹39.2​Cr
Pankaj Prabhakar · Group Chief Financial Officer · p. 6
“As of September 30, 2026, the cash and bank balances stood at INR4,289 million, and net debt stood at INR392 million.”

Debt at peak level for the next few quarters; expected to go down from here

Yatharth Tyagi · Whole · Q&A · p. 12
“But we feel that this is the peak level of debt for us, at least for the next few quarters to come. Debt will eventually go down from here.”

If acquisitions take time, Advent money may be used to reduce debt marginally

Yatharth Tyagi · Whole · Q&A · p. 12
“if the acquisitions take time as far as certain assets are concerned, we can also look to reduce debt marginally from that amount.”

Model Town, Faridabad Sector-20, Gurugram: Around INR100 crores or more of debt taken for medical equipment and Gurugram construction

Yatharth Tyagi · Whole · Q&A · p. 12
“around INR100 crores or more has been taken for certain medical equipment that will be -- and that has been added to both the Model Town Hospital, the Sector 20 Faridabad Hospital, as well as certain construction that is already happening in full swing in the Gurugram Hospital.”

Fund raising

Advent International to invest INR3,150 crores through preferential issue of shares and warrants

Yatharth Tyagi · Whole · p. 3
“we have entered into a strategic partnership with Advent International for a primary capital investment of INR3,150 crores through a preferential issue of equity shares and warrants.”

Advent money in two tranches; first tranche INR1,750 crores after CCI approval this month

Ashutosh Kumar Jha · Group Chief · Q&A · p. 8
“So the Advent money of INR3,150 crores will come in two tranches. The first tranche will be INR1,750 crores, which will be received after the CCI approval this month.”

Second Advent tranche expected after 15 to 18 months, based on conditions

Ashutosh Kumar Jha · Group Chief · Q&A · p. 8
“And the next tranche will be received after 15 to 18 months based on certain conditions.”

Advent deal at final stage of CCI approval; approval expected this month

Yatharth Tyagi · Whole · Q&A · p. 8
“Yes, I think the Advent deal is at the CCI approvals final stages. I think post Diwali, we can expect it to get the approval this month itself.”

Acquisitions and new business

Advent money to buy running, EBITDA-positive assets totalling close to 2,000 beds

Yatharth Tyagi · Whole · Q&A · p. 11
“As we said that we will be acquiring running assets, we will be acquiring EBITDA positive assets, and the total bed capacity that we can look to add from that amount should be close to 2,000 beds in total.”

Acquisition focus on multi-specialty hospitals, larger deals and hospital chains

Ashutosh Kumar Jha · Group Chief · Q&A · p. 8
“Our focus remains on multi-specialty hospitals. Now we are, of course, looking at much larger deals, and we are looking for a chain of hospitals also.”

Hospitals acquired with Advent funds will always be EBITDA positive

Yatharth Tyagi · Whole · Q&A · p. 8
“Also, the assets that we will continue to acquire from this fund will always be EBITDA positive hospitals. There will be no absolute drag on the absolute EBITDA because of these acquisitions going forward.”

No greenfield assets from Advent money; not targeting fully stressed assets

Yatharth Tyagi · Whole · Q&A · p. 17
“I think specifically from the Advent money, we are not creating any greenfield assets, and we might not be going for absolutely stressed assets.”

Advent capital to go mostly into fully owned assets

Yatharth Tyagi · Whole · Q&A · p. 15
“But from the new Advent capital, it would mostly be fully owned assets.”

Risks

oncology: Cancer drug margin cap of 30% reduces EBITDA by around 0.3%

Yatharth Tyagi · Whole · Q&A · p. 7
“We have calculated that, for the existing list of cancer drugs where margins are capped at 30%, the overall impact on our EBITDA numbers is a reduction of around 0.3% because of that specific pricing on oncology drugs.”

international: International business affected in recent months by war and Gulf situation

Amit Kumar Singh · Group Chief Executive Officer · Q&A · p. 11
“However, it has been affected in the last couple of months because of the war , gulf situation and other things.”

Model Town, Delhi: Delhi construction on hold under GRAP 2

Amit Kumar Singh · Group Chief Executive Officer · Q&A · p. 13
“As you know, Delhi is under GRAP 2 now, so construction is on hold.”

Income tax matter resolved with final demand

Yatharth Tyagi · Whole · Q&A · p. 12
“As we were saying, the final demand has come and the matter is resolved now.”

Company advised to appeal against income tax demand

Yatharth Tyagi · Whole · Q&A · p. 13
“Based on legal opinions and even talks with the department itself, we have been advised to appeal against that.”

Other

Q2 FY27 revenue INR4,314 million, up 52% year-on-year and 10% sequentially

Pankaj Prabhakar · Group Chief Financial Officer · p. 5
“The group delivered its highest-ever quarterly revenue of INR4,314 million in quarter 2 FY27, representing growth of 52% year-on-year and 10% sequentially.”

Q2 profit after tax INR485 million, up 17%; H1 PAT INR939 million

Pankaj Prabhakar · Group Chief Financial Officer · p. 6
“Profit after tax stood at INR485 million for quarter 2, up 17% year-on-year, and INR939 million for H1.”

Group ARPOB INR36,000, up 11% year-on-year

Pankaj Prabhakar · Group Chief Financial Officer · p. 5
“Group ARPOB reached an all-time high of INR36,000, up 11% year-on-year.”

Government payer mix 34% this quarter vs 37% last quarter

Yatharth Tyagi · Whole · Q&A · p. 6
“34% is this quarter's government mix, and last quarter it was 37%.”

international: International business around 4%-5%

Yatharth Tyagi · Whole · Q&A · p. 6
“The international business remains close to around 4%-5% at the current payment level.”

Sources

Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

Search

Search funds, ETFs, stocks, pages and tools